GLP-1 Receptor Agonist Dosing for Weight Loss
"Microdosing" GLP-1 receptor agonists is not a recognized or recommended approach—instead, use the FDA-approved gradual dose titration protocols that start low and escalate systematically to therapeutic maintenance doses. The term "microdosing" suggests using subtherapeutic doses indefinitely, which contradicts evidence-based practice and will result in suboptimal weight loss outcomes 1.
Standard Titration Protocols (Not "Microdosing")
Semaglutide 2.4 mg (Weekly Subcutaneous)
The AGA 2022 guidelines specify the following escalation schedule 1:
- Week 1-4: 0.25 mg weekly
- Week 5-8: 0.5 mg weekly
- Week 9-12: 1.0 mg weekly
- Week 13-16: 1.7 mg weekly
- Week 17+: 2.4 mg weekly (maintenance dose)
This 16-week titration minimizes gastrointestinal adverse effects (nausea, vomiting, diarrhea) while achieving the therapeutic dose that produces mean weight loss of 14.9-16.0% at 68 weeks 2.
Liraglutide 3.0 mg (Daily Subcutaneous)
The titration is more rapid 1:
- Week 1: 0.6 mg daily
- Week 2: 1.2 mg daily
- Week 3: 1.8 mg daily
- Week 4: 2.4 mg daily
- Week 5+: 3.0 mg daily (maintenance dose)
This achieves mean weight loss of 8.0% at 56 weeks 2.
Why Gradual Titration Is Essential (Not Optional)
The dose escalation is not "microdosing"—it's a medically necessary strategy to minimize gastrointestinal adverse effects that occur in 47-84% of patients. Nausea affects 40% of liraglutide users and vomiting 16%, compared to 14.8% and 4.3% with placebo 1. Rushing titration or skipping steps increases treatment discontinuation rates (6.1-9.9% with proper titration) 3.
Critical Implementation Points
Staying at Submaximal Doses
Some patients achieve adequate response at submaximal doses and can remain there long-term 1. This is clinical judgment based on:
- Weight loss trajectory (≥5% is clinically meaningful)
- Tolerability of gastrointestinal effects
- Achievement of metabolic goals
However, this is different from intentionally using subtherapeutic doses from the start.
Missed Doses
If 2 consecutive doses are missed 1:
- Resume at the same dose if previously well-tolerated
- Consider lowering one dose level if tolerance was marginal
- Restart full titration if ≥3 consecutive doses missed
Long-Term Use Is Required
Weight regain occurs rapidly after discontinuation—participants regained 11.6% of lost weight within 52 weeks of stopping semaglutide 2. These medications must be used chronically, not as short-term interventions.
Common Pitfalls to Avoid
Using doses below the titration schedule: No evidence supports starting at doses lower than 0.25 mg weekly (semaglutide) or 0.6 mg daily (liraglutide). This delays therapeutic benefit without proven safety advantages.
Prolonging titration beyond recommended timelines: While individual adjustment is acceptable for tolerability, unnecessarily slow escalation keeps patients at subtherapeutic doses longer.
Stopping at intermediate doses without clinical justification: The maintenance doses (2.4 mg semaglutide, 3.0 mg liraglutide) are where maximal weight loss occurs in clinical trials 2, 1.
Monitoring and Adjunctive Measures
Combine GLP-1 therapy with lifestyle modifications (reduced-calorie diet, 150-200 minutes weekly physical activity) as these medications are adjuncts, not monotherapy 2, 1.
Monitor for:
- Gastrointestinal symptoms: Most common during dose escalation, typically mild-to-moderate 4
- Gallbladder disease and pancreatitis: Rare but associated risks 1
- Hypoglycemia: Only if combined with insulin or sulfonylureas 1
- Nutritional deficiencies: Vitamin D (13.6% at 12 months), iron depletion, protein insufficiency 5
Bottom Line
There is no evidence-based "microdosing" protocol for GLP-1 receptor agonists. Use the FDA-approved titration schedules that systematically escalate to therapeutic maintenance doses over 4-16 weeks. Semaglutide 2.4 mg weekly is prioritized over other agents given its superior efficacy (mean 14.9% weight loss) 1. The gradual dose escalation is designed to optimize tolerability while achieving therapeutic benefit—it is not optional or negotiable for achieving meaningful weight loss and cardiovascular risk reduction.